FDA 483 - Rxhomeo Private Limited - February 01, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Rxhomeo Private Limited, a homeopathic drug manufacturer in Hyderabad, Telangana, India, revealed significant deficiencies across its quality system. The firm lacks numerous essential written procedures for production, process controls, equipment management, and quality control. Additionally, batch production records are incomplete, and there are failures in component release, labeling controls, product specifications, instrument calibration, and stability assessments.
ID · 5de003b0-9d94-49af-8223-b72482805e08